|
Name |
Phomacin B
|
Molecular Formula | C25H37NO5 | |
IUPAC Name* |
(1R,4Z,6S,8S,10E,12S,15S,16S,17S)-6-hydroxy-8-(hydroxymethyl)-10,14,15-trimethyl-17-(2-methylpropyl)-2-oxa-18-azatricyclo[10.7.0.01,16]nonadeca-4,10,13-triene-3,19-dione
|
|
SMILES |
C[C@H]1[C@H]2[C@@H](NC(=O)[C@@]23[C@@H](/C=C(/C[C@@H](C[C@@H](/C=C\C(=O)O3)O)CO)\C)C=C1C)CC(C)C
|
|
InChI |
InChI=1S/C25H37NO5/c1-14(2)8-21-23-17(5)16(4)11-19-10-15(3)9-18(13-27)12-20(28)6-7-22(29)31-25(19,23)24(30)26-21/h6-7,10-11,14,17-21,23,27-28H,8-9,12-13H2,1-5H3,(H,26,30)/b7-6-,15-10+/t17-,18+,19+,20-,21+,23+,25-/m1/s1
|
|
InChIKey |
IXONDWQZWWLZDF-ZCMVJGEESA-N
|
|
Synonyms |
Phomacin B; (3Z,5S,7S,9E,10aS,13S,13aS,14S,16aR)-5-hydroxy-7-(hydroxymethyl)-9,12,13-trimethyl-14-(2-methylpropyl)-6,7,8,10a,13,13a,14,15-octahydro-2H-oxacyclododecino[2,3-d]isoindole-2,16(5H)-dione; CHEBI:66747; Q27135371; (1R,4Z,6S,8S,10E,12S,15S,16S,17S)-6-hydroxy-8-(hydroxymethyl)-10,14,15-trimethyl-17-(2-methylpropyl)-2-oxa-18-azatricyclo[10.7.0.01,16]nonadeca-4,10,13-triene-3,19-dione
|
|
CAS | NA | |
PubChem CID | 10622584 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 431.6 | ALogp: | 2.7 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 95.9 | Aromatic Rings: | 3 |
Heavy Atoms: | 31 | QED Weighted: | 0.468 |
Caco-2 Permeability: | -4.736 | MDCK Permeability: | 0.00008540 |
Pgp-inhibitor: | 0.946 | Pgp-substrate: | 0.991 |
Human Intestinal Absorption (HIA): | 0.856 | 20% Bioavailability (F20%): | 0.55 |
30% Bioavailability (F30%): | 0.8 |
Blood-Brain-Barrier Penetration (BBB): | 0.967 | Plasma Protein Binding (PPB): | 71.21% |
Volume Distribution (VD): | 0.848 | Fu: | 17.91% |
CYP1A2-inhibitor: | 0.039 | CYP1A2-substrate: | 0.089 |
CYP2C19-inhibitor: | 0.235 | CYP2C19-substrate: | 0.181 |
CYP2C9-inhibitor: | 0.254 | CYP2C9-substrate: | 0.078 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.153 |
CYP3A4-inhibitor: | 0.85 | CYP3A4-substrate: | 0.24 |
Clearance (CL): | 12.037 | Half-life (T1/2): | 0.436 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.685 |
Drug-inuced Liver Injury (DILI): | 0.283 | AMES Toxicity: | 0.179 |
Rat Oral Acute Toxicity: | 0.737 | Maximum Recommended Daily Dose: | 0.895 |
Skin Sensitization: | 0.225 | Carcinogencity: | 0.429 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.012 |
Respiratory Toxicity: | 0.975 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005825 | 0.637 | D06WTZ | 0.252 | ||||
ENC004242 | 0.573 | D0H0ND | 0.239 | ||||
ENC005810 | 0.571 | D0E9KA | 0.239 | ||||
ENC001855 | 0.528 | D0R2KF | 0.239 | ||||
ENC005136 | 0.514 | D0W2EK | 0.236 | ||||
ENC003433 | 0.495 | D0F1EX | 0.233 | ||||
ENC005809 | 0.491 | D05AFC | 0.229 | ||||
ENC003740 | 0.491 | D03IKT | 0.223 | ||||
ENC002636 | 0.486 | D0K7LU | 0.220 | ||||
ENC004462 | 0.486 | D08PIQ | 0.217 |